Compare Ginkgo Bioworks Holdings Inc (DNA) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs GoPro Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while GoPro Inc trades at $0.7 (market cap $120.72M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 4.9× GoPro Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| DNA | GPRO | |
|---|---|---|
Market Cap | $590.53M | $120.72M |
Sector | Health | Technology |
52-Week High | $16.14 | $2.88 |
52-Week Low | $5.48 | $0.64 |
Enterprise Value | $627.78M | $168.66M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
GoPro (GPRO) trades at $0.711, down 6.79% on the day, reflecting persistent operational challenges and negative investor sentiment. The stock exhibits a bearish technical outlook with consecutive earnings misses, declining revenue from $1.1B in 2022 to $652M in 2025, and negative net income margins. Recent news highlights a strategic review for potential sale or merger amid financial distress, including a $20M financing injection from CEO Nicholas Woodman in July 2026 to bolster liquidity.
The investment outlook remains highly speculative, with opportunities tied to a potential strategic transaction offering upside, but severe risks include going-concern warnings, cash burn, and competitive pressures. Analyst consensus is cautious, with only 21% buy ratings, emphasizing the binary nature of outcomes based on the company's ability to secure a lifeline or execute a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
